AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis

AbbVie's Juvmo, combined with levodopa, provided patients 1.7 more hours of controlled, dyskinesia-free time daily compared to 0.6 hours for placebo. The company partnered with Valkai AI to enhance clinical R&D with AI tools, aiming to improve efficiency and shorten timelines. According to GuruFocus, these figures reflect the mean treatment effect.

AbbVie Inc. (NYSE: ABBV) reported that its drug zumilokibart met primary endpoints in a Phase 2 trial for atopic dermatitis. The company has a 2.57% dividend yield, 85% payout ratio, and 5.2% 3-year dividend growth. Its GF Value suggests a 19.0% overvaluation. AbbVie's GF Score is 77/100, with strong profitability but weaker financial strength.

AbbVie reported that all three dose regimens of its drug zumilokibart met the primary endpoint in a Phase 2 study for atopic dermatitis, with the mid-dose showing early improvements. The drug, an anti-IL-13 monoclonal antibody, aims to offer extended dosing intervals in a crowded market valued at $20.69 billion in 2025. Secondary endpoints also supported the mid- and high-dose regimens, with safety profiles consistent with similar drugs.

AbbVie (ABBV) reported positive Phase 2 results for zumilokibart in treating moderate to severe atopic dermatitis. All doses met the primary endpoint, with the mid-dose selected for Phase 3 trials. The study showed significant improvements in skin lesions and itch compared to placebo. The drug is a half-life extended monoclonal antibody targeting IL-13. The results were presented at the EADV 2026 Congress.

AbbVie (ABBV) will present 60 abstracts at the 2026 EADV Congress, showcasing data on its dermatology portfolio, including SKYRIZI (risankizumab) and RINVOQ (upadacitinib). New data on investigational compounds lutikizumab and zumilokibart will also be shared, covering diseases like alopecia areata, atopic dermatitis, and hidradenitis suppurativa.

AbbVie (ABBV) announced positive Phase 2 results for zumilokibart, a treatment for moderate to severe atopic dermatitis, at the EADV 2026 Congress. All three dose regimens met the primary endpoint, showing significant improvements in EASI-75 response rates versus placebo at Week 16. The mid-dose regimen was selected for Phase 3 development. Zumilokibart is a monoclonal antibody targeting IL-13.